Stryker shares tumble despite strong Q2 results and raised guidance
FREMONT, Calif. - Tivic Health Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that it has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock, currently trading at $4.82, will continue to be listed on the Nasdaq Capital Market. According to InvestingPro data, the stock has shown strong momentum with an 11.85% return over the past six months, despite experiencing significant volatility.
This development comes as a relief for Tivic Health, as meeting the Nasdaq Listing Rule 5550(a)(2) is crucial for maintaining its presence on the market. The rule stipulates that companies must maintain a minimum bid price of $1.00 per share, and falling below this threshold can lead to delisting. InvestingPro analysis shows the company maintains a healthy current ratio of 9.7, with liquid assets exceeding short-term obligations.
Tivic Health is known for its focus on leveraging the immune and autonomic nervous systems to combat disease and improve health. Its bioelectronic division develops non-invasive medical devices, including an FDA-approved device for sinus pain relief named ClearUP®. The biopharma division is advancing Entolimod™, a TLR5 agonist, through late-stage studies for treating acute radiation syndrome (ARS), with Fast Track and Orphan Drug designations from the FDA.
The company is also preparing to file an investigational new drug application and initiate a phase 2 clinical study for the treatment of Neutropenia, and it has options to license additional indications related to immune system conditions. While analysts project 9.3% revenue growth for FY2025, InvestingPro's comprehensive analysis indicates the stock is currently trading near its Fair Value. For deeper insights, investors can access the detailed Pro Research Report, available exclusively to InvestingPro subscribers, covering this and 1,400+ other US equities.
The news about Tivic Health's compliance with Nasdaq's listing requirements is based on a press release statement and does not reflect any endorsement of the company's financial health or future performance. It is important for investors to consider the company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, for a comprehensive understanding of the risks and uncertainties Tivic Health faces.
In other recent news, Tivic Health Systems reported a 33% decline in revenue for the first quarter of 2025, totaling $800,000 compared to the previous year's $1.2 million. Despite this revenue drop, the company improved its net loss to $5.7 million from $8.2 million in the prior year, indicating effective cost management. Tivic Health has expanded its licensing agreement with Statera Biopharma for the development of a treatment for Neutropenia, granting it exclusive worldwide rights to the Entolimod program. The company has issued additional equity securities to Statera and Avenue Venture Opportunities Fund as part of this agreement. Tivic Health is also focusing on the commercialization of Entelimod, a Phase Three drug candidate, and aims to file for an FDA Biologics License Application within 18 months. Additionally, the company has secured a $25 million equity line of credit to support its development stages. The strategic expansion into immunotherapy and neuromodulation markets is part of Tivic Health's broader initiative to diversify its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.